NeuroSense Therapeutics (NASDAQ:NRSN) CEO Alon Ben-Noon Buys 250,000 Shares of Stock

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) CEO Alon Ben-Noon acquired 250,000 shares of the business’s stock in a transaction dated Tuesday, June 16th. The shares were acquired at an average cost of $0.80 per share, with a total value of $200,000.00. Following the transaction, the chief executive officer owned 4,534,233 shares in the company, valued at approximately $3,627,386.40. This trade represents a 5.84% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

NeuroSense Therapeutics Price Performance

Shares of NASDAQ NRSN opened at $0.71 on Thursday. The firm has a fifty day moving average price of $0.78 and a 200-day moving average price of $0.86. The stock has a market cap of $22.95 million, a PE ratio of -1.31 and a beta of 1.56. NeuroSense Therapeutics Ltd. has a 1 year low of $0.63 and a 1 year high of $2.52.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of NRSN. Jane Street Group LLC purchased a new stake in NeuroSense Therapeutics in the second quarter worth $54,000. Squarepoint Ops LLC raised its holdings in shares of NeuroSense Therapeutics by 91.0% in the 3rd quarter. Squarepoint Ops LLC now owns 95,375 shares of the company’s stock valued at $119,000 after purchasing an additional 45,450 shares in the last quarter. Two Sigma Investments LP purchased a new stake in shares of NeuroSense Therapeutics in the 3rd quarter worth approximately $26,000. Finally, Yorkville Advisors Global LP bought a new position in shares of NeuroSense Therapeutics during the fourth quarter valued at approximately $77,000. Institutional investors own 1.04% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have commented on NRSN shares. Roth Mkm assumed coverage on shares of NeuroSense Therapeutics in a research report on Tuesday, March 10th. They set a “buy” rating and a $3.00 price objective for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NeuroSense Therapeutics in a report on Friday, May 8th. Finally, D. Boral Capital reissued a “buy” rating and set a $14.00 price objective on shares of NeuroSense Therapeutics in a research note on Wednesday, April 8th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, NeuroSense Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $8.50.

About NeuroSense Therapeutics

NeuroSense Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative and age-related neurological disorders. The company’s primary mission is to address unmet medical needs in diseases characterized by protein aggregation, chronic inflammation and cellular senescence in the central nervous system.

At the core of NeuroSense’s approach is a proprietary senotherapeutic platform designed to selectively target and clear senescent cells that contribute to neurodegeneration.